Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation01:24

One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation

566
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
566
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

764
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
764

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Solvent Effects on the Photophysical Properties of Unexplored Imidazo[1,2‑<i>a</i>]pyridine Derivatives.

ACS omega·2026
Same author

Expanding the Palette of Molecular Fragments for Small Molecule De Novo Design Through Isosteric Swapping.

Journal of computational chemistry·2026
Same author

Development of Receptor Desolvation Scoring and Covalent Sampling in DOCK 6: Methods Evaluated on a RAS Test Set.

Journal of chemical information and modeling·2025
Same author

Mutations in Mig6 reduce inhibition of the epidermal growth factor receptor.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2024
Same author

Fragment and torsion biasing algorithms for construction of small organic molecules in proteins using DOCK.

Journal of computational chemistry·2024
Same author

Revisiting Biginelli-like reactions: solvent effects, mechanisms, biological applications and correction of several literature reports.

Organic & biomolecular chemistry·2024
Same journal

QSAR in the Browser: An Interactive Cheminformatics Web Application.

Journal of chemical information and modeling·2026
Same journal

FoldDoF: Utilizing the Primary Degrees of Freedom of Protein Backbone for Geometric Modeling and Generation.

Journal of chemical information and modeling·2026
Same journal

Derisking Affinity Optimization for Macrocycles and Cyclic Peptides: High-Precision Free Energy Simulations across Five Diverse Targets.

Journal of chemical information and modeling·2026
Same journal

An End-User Audit of Reproducibility, Data Leakage, and Overfitting of the Top-Ranked ADMET Prediction Models in TDC Leaderboards.

Journal of chemical information and modeling·2026
Same journal

PFASGroups: An Open-Source Framework for Automated Identification, Structural Classification, and Prioritization of Per- and Polyfluoroalkyl Substances.

Journal of chemical information and modeling·2026
Same journal

DeepKbhb: Context-Aware Prediction of Human Lysine β-Hydroxybutyrylation Sites.

Journal of chemical information and modeling·2026
See all related articles

Related Experiment Video

Updated: Jul 16, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Descriptor-Driven de Novo Design Algorithms for DOCK6 Using RDKit.

Guilherme Duarte Ramos Matos1,2, Steven Pak3, Robert C Rizzo1,4,5

  • 1Department of Applied Mathematics & Statistics, Stony Brook University, Stony Brook, New York 11794, United States.

Journal of Chemical Information and Modeling
|September 12, 2023
PubMed
Summary
This summary is machine-generated.

A new Descriptor-Driven De Novo (D3N) strategy in DOCK6 utilizes RDKit to design drug leads. This method guides molecule construction by calculating cheminformatics descriptors, enabling targeted chemical space exploration for drug discovery.

More Related Videos

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

318
Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

71

Related Experiment Videos

Last Updated: Jul 16, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

318
Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

71

Area of Science:

  • Computational chemistry
  • Drug discovery
  • Cheminformatics

Background:

  • De novo design is crucial for discovering novel drug leads by constructing molecules computationally.
  • Existing methods may lack precise control over the chemical space explored during molecular construction.

Purpose of the Study:

  • To introduce and validate a Descriptor-Driven De Novo (D3N) strategy within the DOCK6 software.
  • To enable tailored ligand design by calculating user-defined cheminformatics descriptors during molecular growth.

Main Methods:

  • Integration of the RDKit toolkit into DOCK6 for on-the-fly descriptor calculations.
  • Implementation of the D3N strategy to guide ligand growth based on specified descriptor ranges.
  • Validation through comparison of descriptor calculations, analysis of descriptor distributions, and construction of ligands with tight descriptor constraints.

Main Results:

  • Robustness of the DOCK6/RDKit integration confirmed.
  • Demonstration of D3N's capability to direct molecular sampling within user-defined chemical spaces.
  • Successful construction of ligands with precise descriptor profiles, referencing clinically relevant compounds.

Conclusions:

  • The D3N strategy enhances DOCK6 for targeted drug-lead discovery.
  • On-the-fly descriptor calculations offer a powerful approach for designing ligands with desired properties.
  • This integration facilitates exploration of specific chemical spaces relevant to drug targets.